A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low dose in Addition to NACT in TNBC).
Arora A, Bhaskarane H, Tansir G, Bakhshi S, Gogia A, Kumar A, Jain R, Kalra K, Vishvam D, Mathur S, Rathore R, Shamim SA, Dhamija E, Rangarajan K, Tanwar P, Prasad CP, Kumar S, Gupta I, Mani K, Upadhyay AD, Divakar MK, Vasudeva P, Verma N, Agstam S, Vuthaluru S, Parshad R, Bansal VK, Dhar A, Krishna A, Ranjan P, Suhani S, Prakash O, Kataria K, Kumar B, Mishra A, Sharma J, Bansal B, Saikia J, Bhasker S, Haresh KP, Gupta S, Saini SK, Mallick S, Batra A.
Arora A, et al. Among authors: agstam s.
Ann Oncol. 2026 May;37(5):639-649. doi: 10.1016/j.annonc.2025.12.015. Epub 2025 Dec 22.
Ann Oncol. 2026.
PMID: 41443410
Clinical Trial.